Drug Safety

, Volume 26, Issue 14, pp 991–997 | Cite as

Health Risks of Counterfeit Pharmaceuticals

Current Opinion

Abstract

Pharmaceutical products are not exempt from the practice of counterfeiting. In recent years, many reports have become available demonstrating the presence of fake medicines on the market. Several studies have demonstrated that they are quite often of bad quality.

It is estimated that 5% of all world trade in branded goods is counterfeit, leading to huge financial losses for the pharmaceutical industry. But much more important, from a public health point of view, is that history has shown that such products may lead to a great health risk. The essence of counterfeit products and the reason they are so dangerous is the complete absence of quality control, since they are often indistinguishable from the genuine product.

The existence of counterfeit drugs has long been ignored both by the pharmaceutical industry and by drug regulatory authorities. At present initiatives are being taken, nationally and internationally, to curb counterfeiting. It is now realised that a strong regulatory agency is essential, but the initiatives can only be successful if all parties concerned actively co-operate.

References

  1. 1.
    Counterfeit Drugs. Report of a joint WHO/IFPMA Workshop. Geneva: World Health Organization, 1992Google Scholar
  2. 2.
    The Diethylene Glycol Contamination Prevention Workshop. Co-sponsored by CDC, FDA. Washington, DC: PAHO, 1997Google Scholar
  3. 3.
    Ten Ham M. Counterfeit drugs: implications for health. Adverse Drug React Toxicol Rev 1992; 11(1): 59–65PubMedGoogle Scholar
  4. 4.
    Banerjee A. Fake polio vaccine kills 11 children in Nadia [newspaper report]. The Asian Age 1995 Apr 5Google Scholar
  5. 5.
    Cuff R. United Kingdom guidelines on counterfeit drugs. Drug Inf J 1996; 29: 633–7CrossRefGoogle Scholar
  6. 6.
    New anticounterfeiting bill strengthens enforcement. Authentication News 2002 Sep; 8 (7)Google Scholar
  7. 7.
    Opinion of the Economic and Social Committee on “Counterfeiting” (2001/C211/02). Official Journal of the European Communities, 2001 Aug 7Google Scholar
  8. 8.
    The Product Surety Center. A resource center for industries and government agencies involved in ensuring the security and safety of products [online]. Available from URL: http://www.productsurety.org [Accessed 2003 Sep 29]Google Scholar
  9. 9.
    LeParc M, editor. Protecting medicines and pharmaceuticals: a manual of anticounterfeiting solutions. Reconnaissance International, 2002 [online]. Available from URL: http://www.reconnaissance-intl.com/reconnaissance/pharma/index.html [Accessed 2003 Set 29]
  10. 10.
    Counterfeit Drugs. Report of the International Workshop on Counterfeit Drugs. Geneva, Switzerland: World Health Organization, 1997Google Scholar
  11. 11.
    Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs. Geneva, Switzerland: World Health Organization, 1999Google Scholar
  12. 12.
    Bruneton C. Qualité des médicaments génériques antituberculeux au Tchad. Réseau Médicaments & Développement (ReMeD) 1997 Dec: 18Google Scholar
  13. 13.
    Wondemagnehu E. Counterfeit and substandard drugs in Myanmar and Viet Nam. Report of a study. Geneva: World Health Organization, 1999 (unpublished document)Google Scholar
  14. 14.
    Poole D. Drug distribution and fake drugs in Nigeria: international workshop. Institute for Medical Informatics. Lagos, Nigeria, 1989Google Scholar
  15. 15.
    Pakistan tackles counterfeits. SCRIP, 1999Google Scholar
  16. 16.
    Vietnam: fake drugs sales down sharply. Marketletter 1998 JanGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Department of Pharmaceuticals and Medical TechnologyMinistry of Public Health, Welfare and SportDen HaagThe Netherlands

Personalised recommendations